知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

58 条记录 (耗时 0.029 秒)

    Recombinant human interferon-like proteins
    1.
    发明授权
    Recombinant human interferon-like proteins 有权
    重组人干扰素样蛋白

    公开(公告)号：US08425895B2

    公开(公告)日：2013-04-23

    申请号：US12665682

    申请日：2007-06-22

    申请人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

    发明人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

    IPC分类号： A61K38/21 ,  C07K14/00 ,  C08H1/02 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

    CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555

    摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

    摘要翻译： 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

    Object pose normalization method and apparatus and object recognition method
    3.
    发明授权
    Object pose normalization method and apparatus and object recognition method 有权
    对象姿态归一化方法及装置与对象识别方法

    公开(公告)号：US08055028B2

    公开(公告)日：2011-11-08

    申请号：US11889427

    申请日：2007-08-13

    申请人： Gyu-tae Park ,  Haitao Wang ,  Young-su Moon

    发明人： Gyu-tae Park ,  Haitao Wang ,  Young-su Moon

    IPC分类号： G06K9/00

    CPC分类号： G06T7/73 ,  G06T2207/30201

    摘要： An object pose normalization method and apparatus and an object recognition method are provided. The object pose normalization method includes: determining a pose of a non-frontal image of an object; performing smoothing transformation on the non-frontal image of the object, thereby generating a smoothed object image; and synthesizing a frontal image of the object by using the pose determination result and the smoothed object image. According to the method and apparatus, a front object image can be synthesized by using a non-frontal object image without causing an image distortion problem due to self-occlusion and non-rigid deformation.

    摘要翻译： 提出了一种物体姿态归一化方法和装置以及物体识别方法。 对象姿态归一化方法包括：确定对象的非正面图像的姿态; 对对象的非正面图像执行平滑变换，从而生成平滑对象图像; 以及通过使用姿势确定结果和平滑的对象图像合成对象的正面图像。 根据该方法和装置，可以通过使用非正面对象图像来合成正面对象图像，而不会由于自闭和非刚性变形而引起图像失真问题。

    SOLAR-POWERED DEVICE
    4.
    发明申请
    SOLAR-POWERED DEVICE 审中-公开
    太阳能设备

    公开(公告)号：US20100001681A1

    公开(公告)日：2010-01-07

    申请号：US12423161

    申请日：2009-04-14

    申请人： Yazhao Zhang ,  Wu Yang ,  Dahong Zhou ,  Haitao Wang

    发明人： Yazhao Zhang ,  Wu Yang ,  Dahong Zhou ,  Haitao Wang

    IPC分类号： H01M10/46 ,  H01L31/048

    CPC分类号： H02J7/355 ,  H01L31/048 ,  H02S40/38 ,  Y02E10/50

    摘要： Solar-powered device having a body for housing at least one energy storage module and at least one control module are disclosed. The body includes an opening formed by at least two recesses disposed about an upper surface of the body. At least one solar panel may be coupled to the upper surface of the body where the solar panel may be received by the recesses.

    摘要翻译： 公开了具有用于容纳至少一个能量存储模块和至少一个控制模块的主体的太阳能装置。 主体包括由围绕主体的上表面设置的至少两个凹部形成的开口。 至少一个太阳能电池板可以耦合到主体的上表面，其中太阳能电池板可以被凹部接收。

    Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
    5.
    发明授权
    Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo 有权
    重组人EPO-Fc融合蛋白具有延长的半衰期和增强体内红细胞生成活性

    公开(公告)号：US07625564B2

    公开(公告)日：2009-12-01

    申请号：US11340661

    申请日：2006-01-27

    申请人： Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

    发明人： Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

    IPC分类号： A61K39/00 ,  C07K14/00 ,  C07K17/00

    CPC分类号： C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

    摘要： A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

    摘要翻译： 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白在体内具有延长的半衰期。 在本发明的一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白也表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人免疫球蛋白IgG1的Fc片段的肽序列。 融合蛋白中的Fc片段包括人免疫球蛋白IgG1的铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头并且当在体内施用时减轻免疫原性应答的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。本发明还涉及编码融合蛋白和转染的细胞系的核酸和氨基酸序列以及用于产生融合蛋白的方法。 本发明还包括包含融合蛋白的药物组合物和使用融合蛋白和/或药物组合物的方法，例如刺激需要治疗的受试者的红细胞生成。

    Recombinant human interferon-like proteins
    6.
    发明授权
    Recombinant human interferon-like proteins 有权
    重组人干扰素样蛋白

    公开(公告)号：US07625555B2

    公开(公告)日：2009-12-01

    申请号：US11764786

    申请日：2007-06-18

    申请人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    发明人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    IPC分类号： A61K38/21 ,  C07K14/00 ,  C08H1/02 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

    CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555

    摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

    摘要翻译： 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

    Automatic frequency offset compensation in a TDD wireless OFDM communication system
    7.
    发明申请
    Automatic frequency offset compensation in a TDD wireless OFDM communication system 失效
    TDD无线OFDM通信系统中的自动频偏补偿

    公开(公告)号：US20080137563A1

    公开(公告)日：2008-06-12

    申请号：US11651249

    申请日：2007-01-09

    申请人： Haitao Wang

    发明人： Haitao Wang

    IPC分类号： H04J3/06 ,  H04L7/00 ,  H04L27/06

    CPC分类号： H04L27/266 ,  H04L27/2613 ,  H04L27/2659 ,  H04L27/2675

    摘要： Offsets in the transmit clock in a wireless communication system are corrected by using data distributed over many frequencies. In the time domain the system uses separate copies of the same signal transmitted with a known spacing in terms of transmit clock signals. The variation of timing between the received signals yields an initial estimate that then is used in a closed loop tracking arrangement to yield and compensate for unpredictable rate changes caused by, for example, jitter, Doppler or thermal drift. The frequency offset for one channel can then be used to calculate the offset for other channels.

    摘要翻译： 通过使用分布在许多频率上的数据来校正无线通信系统中发射时钟的偏移。 在时域中，系统使用在传输时钟信号方面以已知间隔传输的相同信号的单独副本。 接收信号之间的定时变化产生初始估计，然后将其用于闭环跟踪装置中以产生并补偿由例如抖动，多普勒或热漂移引起的不可预测的速率变化。 然后可以使用一个通道的频率偏移来计算其他通道的偏移量。